Answer
Aug 04, 2026 - 11:19 AM
Tagrisso is prescribed after surgery to prevent lung cancer recurrence, as a first-line treatment for metastatic NSCLC with EGFR mutations, after chemotherapy and radiation in locally advanced unresectable cancer, and when prior EGFR tyrosine kinase inhibitor (TKI) therapy has failed. This broad range of uses provides treatment options for different stages and scenarios in lung cancer care.
